Sage Advice: Reducing the Risk of Hypoglycemia in Older Adults with Diabetes
Hypoglycemia from overtreatment is a serious but seldom recognized complication in older adults with type 2 diabetes. A new decision support tool developed by the Endocrine Society can help primary care providers avoid overtreatment and cut the risk of hypoglycemic events in these patients. The use of a clinical decision support tool can reduce the risk...Advancing Diabetes Research and Care with Digital Education and Knowledge Sharing
More than 100 years after the discovery of insulin galvanized our field, diabetes research and care remain a central part of endocrinology. Diabetes Awareness Month offers the opportunity to reflect on the importance of our research and clinical care to millions of people around the globe. For the 540 million people worldwide living with diabetes,...Pharm Fresh: What Pharmacological Solutions Could Play a Role in Preventing Diabetes?
For decades, physicians have maintained that type 2 diabetes could be delayed or even prevented altogether simply by modifying certain behaviors. Priyanka Majety, MD, talks to Endocrine News about pharmacological options that could help these patients, but lifestyle modifications are still crucial. As we enter National Diabetes Month and head toward World Diabetes Day on...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide)...FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management
